Verastem, Inc. (VSTM)
Verastem, Inc. (VSTM) from its SEC filings: 2025 revenue $30.9 million (+209% vs the year before), net margin -678%, free cash flow -$137.5 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $30.9 million |
| Revenue growth | +209% |
| Net income | -$209.5 million |
| Net margin | -677.6% |
| Free cash flow | -$137.5 million |
| Diluted EPS | $-3.02 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +1775% |
| Cash | $136.4 million |
| Long-term debt | $21.5 million |
| Share count, 1 year | +47% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.